Literature DB >> 16508883

Should antibiotic combinations be used to treat ventilator-associated pneumonia?

Philippe Eggimann1, Jean-Pierre Revelly.   

Abstract

This review summarizes the rationale for using or not using combinations of antibiotics to treat ventilator-associated pneumonia (VAP). Patients suffering from VAP require empirical antibiotic treatment before the identification of an etiologic agent. Most treatment failures are related to inappropriate initial antibiotic treatment with insufficient coverage of multidrug-resistant (MDR) pathogens. Guidelines require initial (empirical) treatment of VAP with a combination of antibiotics. However, this contributes to overexposure to antibiotics and further emergence of MDR microorganisms. We review the rationale for using combinations of antibiotics to cover MDR gram-negatives. However, clinical data supporting this strategy are limited. In fact, systematic combination therapy may have contributed to the overuse of antibiotics and to the emergence of MDR microorganisms. Nevertheless, combination therapy is our best strategy to treat severe infections due to suspected MDR microorganisms. Optimally, therapeutic strategies should be sufficiently broad to cover relevant pathogens while minimizing the risk for emergence of antimicrobial resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16508883     DOI: 10.1055/s-2006-933675

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  4 in total

1.  Mutations in the primary sigma factor σA and termination factor rho that reduce susceptibility to cell wall antibiotics.

Authors:  Yong Heon Lee; John D Helmann
Journal:  J Bacteriol       Date:  2014-08-11       Impact factor: 3.490

2.  Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality.

Authors:  C Peña; S Gómez-Zorrilla; I Oriol; F Tubau; M A Dominguez; M Pujol; J Ariza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-24       Impact factor: 3.267

Review 3.  An Argument for the Use of Aminoglycosides in the Empiric Treatment of Ventilator-Associated Pneumonia.

Authors:  Addison K May
Journal:  Surg Infect (Larchmt)       Date:  2016-04-01       Impact factor: 2.150

4.  Accelerated evolution of resistance in multidrug environments.

Authors:  Matthew Hegreness; Noam Shoresh; Doris Damian; Daniel Hartl; Roy Kishony
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.